New drug 610 aims to tame severe asthma attacks
NCT ID NCT06323213
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a new drug called 610 in 480 Chinese adults with severe eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. Participants receive either 610 or a placebo injection for 52 weeks. The main goal is to see if 610 reduces the number of severe asthma attacks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
610 (a drug injected under the skin)
What this could lead to
If it works, this could offer a new treatment option to reduce severe asthma attacks for people with hard-to-control eosinophilic asthma.
What could go wrong
This is a Phase 3 trial, but it's still experimental. The drug may not work better than placebo, and side effects are possible. Results may only apply to Chinese adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, China